FIELD: biotechnology.
SUBSTANCE: monoclonal antibody or its antigen-binding fragment that bind to human β-Clotho are proposed. Nucleic acids encoding the specified antibody, an expression vector, and a host cell that are used in an antibody production method are also proposed. In addition, pharmaceutical compositions and methods for a decrease in body weight, reduction in appetite or food consumption, reduction in TG concentration in blood plasma or TC concentration in blood plasma in an individual, treatment of a metabolic FGF21-associated disorder, atherosclerosis, peripheral arterial disease, stroke, heart failure or coronary heart disease are presented.
EFFECT: invention provides for the activation of a receptor complex of the human fibroblast growth factor 21 (hereinafter – FGF21) and FGF21-mediated signal transmission using FGF21 mimetic antibodies with improved stability characteristics.
29 cl, 11 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATING FGF21-RELATED DISORDERS | 2016 |
|
RU2752530C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
